Clinical Trial Update: Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating erlotinib with or without fulvestrant in stage IIIB or IV non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: Translational Oncology Research International | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED